Importantly, targeting TIGIT with anti-TIGIT antibodies not only enhanced the antitumor activities of T cells but also suppressed the abundance of IL-32, in turn inhibiting the metastasis of bladder cancer cells. Here, TIGIT is linked to urinary bladder cancer.